About RareCyte
RareCyte is a company based in Seattle (United States) founded in 2009. RareCyte has raised $114.33 million across 9 funding rounds from investors including Agilent, HHS and The Forest Road Company. RareCyte offers products and services including Orion Spatial Imager, CyteFinder II, AccuCyte Sample Prep System, RarePlex Panel Kits, and Precision Biology Services. RareCyte operates in a competitive market with competitors including ArcherDX, Neogen, Parse Biosciences, Qiagen and Variantyx, among others.
- Headquarter Seattle, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Rarecyte, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$114.33 M (USD)
in 9 rounds
-
Latest Funding Round
$20 M (USD), Series C
Jun 27, 2024
-
Investors
Agilent
& 11 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of RareCyte
RareCyte offers a comprehensive portfolio of products and services, including Orion Spatial Imager, CyteFinder II, AccuCyte Sample Prep System, RarePlex Panel Kits, and Precision Biology Services.
Enables high-plex spatial imaging for faster research insights.
Automates rare cell imaging and retrieval for clinical applications.
Prepares samples for liquid biopsy and molecular analysis.
Facilitates biomarker detection in spatial biology studies.
Offers custom assay development for research and trials.
People of RareCyte
Unlock access to complete
Unlock access to complete
Funding Insights of RareCyte
RareCyte has successfully raised a total of $114.33M across 9 strategic funding rounds. The most recent funding activity was a Series C round of $20 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Series C — $20.0M
- First Round First Round
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2024 | Amount | Series C - RareCyte | Valuation | F-Prime Capital , Arboretum Ventures | |
| Jul, 2023 | Amount | Series C - RareCyte | Valuation |
investors |
|
| Sep, 2021 | Amount | Series C - RareCyte | Valuation | Arboretum Ventures |
Investors in RareCyte
RareCyte has secured backing from 12 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Agilent, HHS and The Forest Road Company.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Founded Year | Domain | Location | |
|
Healthcare venture capital investments are made by Arboretum Ventures.
|
Founded Year | Domain | Location | |
|
Investments are focused on tech and life sciences startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by RareCyte
Financial Statements - RareCyte
Rarecyte Comparisons
Competitors of RareCyte
RareCyte operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ArcherDX, Neogen, Parse Biosciences, Qiagen and Variantyx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| domain | founded_year | HQ Location |
Manufacturer of products in the areas of veterinary diagnostics, life sciences, DNA testing, and drug testing
|
|
| domain | founded_year | HQ Location |
RNA-sequencing transcriptome kits for health data analysis are developed.
|
|
| domain | founded_year | HQ Location |
Products and reagents for molecular diagnostic assays are supplied.
|
|
| domain | founded_year | HQ Location |
Genomics data analysis platform for healthcare diagnostics is offered.
|
|
| domain | founded_year | HQ Location |
Molecular diagnostic assays are developed for target DNA sequence detection.
|
Latest news on Rarecyte
Frequently Asked Questions about RareCyte
RareCyte was founded in 2009 and raised its 1st funding round 3 years after it was founded.
RareCyte is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
RareCyte is a funded company, having raised a total of $114.33M across 9 funding rounds to date. The company's 1st funding round was a Series C of $24M, raised on Aug 21, 2012.
RareCyte was founded in 2009 in Seattle, United States, within the biotechnology sector. Technologies are provided for the preparation and multiparametric phenotypic analysis of rare cells from blood samples. Individual rare cell capture and retrieval for genomic analysis are supported. The platform integrates AccuCyte, a blood separation system, with CyteFinder, an instrument for cell imaging and analysis, facilitating operations in clinical and research settings.
RareCyte offers Orion Spatial Imager, CyteFinder II, AccuCyte Sample Prep System, RarePlex Panel Kits, and Precision Biology Services.
RareCyte has 12 investors. Key investors include Agilent, HHS, The Forest Road Company, F-Prime Capital, and Arboretum Ventures.